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Abstract  
The congenital myopathies – including Central Core Disease (CCD), Multi-minicore Disease 
(MmD), Centronuclear Myopathy (CNM), Nemaline Myopathy (NM) and Congenital Fibre Type 
Disproportion (CFTD) – are a genetically heterogeneous group of early-onset neuromuscular 
conditions characterized by distinct histopathological features, and associated with a substantial 
individual and societal disease burden. Appropriate supportive management has substantially 
improved patient morbidity and mortality but there is currently no cure.     
Recent years have seen an exponential increase in the genetic and molecular understanding of 
these conditions, leading to the identification of underlying defects in proteins involved in calcium 
homeostasis and excitation-contraction coupling, thick/thin filament assembly and function, redox 
regulation, membrane trafficking and/or autophagic pathways. Based on these findings, specific 
therapies are currently being developed, or are already approaching the clinical trial stage. Despite 
undeniable progress, therapy development faces considerable challenges, considering the rarity 
and diversity of specific conditions, and the size and complexity of some of the genes and proteins 
involved.    
The present review will summarize the key genetic, histopathological and clinical features of 
specific congenital myopathies, and outline therapies already available or currently being 
developed in the context of known pathogenic mechanisms. The relevance of newly discovered 
molecular mechanisms and novel gene editing strategies for future therapy development will be 
discussed.   
 
 
Key words: 
CCD = Central Core Disease; CFTD = Congenital Fibre Type Disproportion; CNM = 
Centronuclear Myopathy; MmD = Multi-minicore Disease; NM = Nemaline Myopathy  
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1. Introduction 
 
The congenital myopathies are a group of clinically heterogeneous, early-onset 
neuromuscular disorders characterized by normal CK and defined features on muscle biopsy (for 
review, [1]). Central Core Disease (CCD) and Multi-minicore Disease (MmD) (the “core 
myopathies), Nemaline Myopathy (NM), Centronuclear Myopathy (CNM) and Congenital Fibre 
Type Disproportion (CFTD) are the major entities. There are additional rarer forms, often limited 
to few families or patients.  
The last decade has seen an exponential increase in the genetic resolution of the congenital 
myopathies. Mutations in almost 20 genes have been identified (Table 1), indicating both genetic 
diversity and substantial overlap between conditions previously considered to be distinct. Different 
mutations in the same gene may cause distinct congenital myopathies depending on the protein 
domain affected, whilst mutations in different genes may cause overlapping histopathological 
appearances due to functional association of the defective gene products. Mutations in the skeletal 
muscle ryanodine receptor (RYR1) gene, encoding the principal sarcoplasmic reticulum (SR) 
calcium release channel with a crucial role in excitation-contraction coupling, have emerged as the 
most common genetic cause implicated in most of the major forms [2, 3]. Proteins affected in the 
congenital myopathies are involved in calcium homeostasis and excitation-contraction coupling, 
thick/thin filament assembly and interactions, redox regulation, vesicular trafficking and/or 
autophagic pathways (Figure 1). In contrast to the congenital muscular dystrophies, sarcolemmal 
integrity is preserved, reflected in typically normal CK levels.            
There is currently no cure for any of the congenital myopathies and management is largely 
supportive, aimed at preserving mobility and addressing orthopaedic, cardiorespiratory and other 
potential comorbidities such as an increased malignant hyperthermia (MH) risk (outlined in detail 
in [4]).  
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Therapy development in the congenital myopathies faces a number of clinical and 
molecular challenges, some in common with other early-onset neuromuscular disorders and others 
more specific. On the clinical level, overall rarity of specific conditions and the marked clinical 
diversity associated with specific genetic defects makes recruitment for meaningful clinical trials a 
daunting task. On the molecular level, the sheer size and complexity of some of the proteins 
involved precludes viral transfer of the functional gene or exon skipping strategies as viable 
therapeutic options in many of these conditions. In addition, some of the underlying mechanisms 
are currently only partially understood.   
The present review will summarize the key features of specific congenital myopathies, 
relevant animal models, and underlying pathogenic mechanisms (where known) as a basis for 
therapy development. We will outline currently available therapeutic approaches (Table 1) and the 
rationale behind potential future treatment strategies.  
 
2. Core myopathies 
 
The core myopathies (for detailed review, see [5]) are characterized by variable 
histopathological abnormalities on oxidative enzyme stains, well-defined and running along the 
longitudinal fibre axis in Central Core Disease (CCD) [6], and of more limited extent and patchier 
appearance in Multi-minicore Disease (MmD) [7]. As a group, core myopathies represent the most 
common subset of congenital myopathies, as recently confirmed in two independent studies from 
the USA and the United Kingdom [2, 3]. Core myopathies are most commonly linked to dominant 
and recessive mutations in the RYR1 gene, or recessive mutations in the SEPN1 gene encoding 
selenoprotein N. The histopathological appearance of cores on muscle biopsy is, however, not 
specific, and other genetic backgrounds, for example mutations in TTN [8] or MYH7 [9] have to be 
considered, in particular if cardiac involvement is a feature and/or minicores are present.  
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Dominant mutations in RYR1 are most commonly associated with the malignant 
hyperthermia susceptibility (MHS) trait [10], a pharmacogenetic reaction to halogenated 
anaesthetics and muscle relaxants, and CCD, a relatively mild, predominantly proximal congenital 
myopathy typically without significant extraocular or cardiorespiratory involvement. MHS-related 
RYR1 mutations have also been associated with “induced” or adult-onset neuromuscular 
phenotypes, in particular exertional rhabdomyolysis [11] and late-onset axial myopathy [12]. 
Recessive mutations in RYR1 mainly cause Multi-minicore Disease with external ophthalmoplegia 
[13], but also subgroups of Centronuclear Myopathy (CNM) [14] and Congenital Fibre Type 
Disproportion (CFTD) [15] (see below). Recessive mutations in SEPN1 are the second most 
common cause of core myopathies [16], typically associated with the histopathological phenotype 
of MmD and clinical features of a predominantly axial myopathy with marked spinal rigidity, 
early-onset scoliosis and respiratory impairment almost invariably requiring respiratory support; 
congenital muscular dystrophy with spinal rigidity [17] and Mallory body myopathy [18] are 
allelic histopathological presentations .   
  Whereas the pathomechanisms underlying dominantly inherited RYR1-related MHS and 
CCD have been investigated in detail, recessive forms of RYR1-related myopathies remain only 
partially understood, with important implications for the development of therapeutic strategies. 
Whilst MHS and related phenotypes are generally attributed to a ”hyperactive” RyR1 channel 
reflective of increased RyR1 agonist sensitivity and resulting disproportionate calcium release 
upon RyR1 stimulation,  depletion of sarcoplasmic reticulum calcium stores with resulting 
increase in cytosolic calcium levels (”leaky channel” hypothesis) and disturbance of excitation-
contraction coupling (E-C uncoupling hypothesis) have been proposed as explanations for RyR1 
receptor malfunction in CCD and related myopathies (reviewed in [5]). Most functional studies 
concerning recessive RYR1 mutations published to date indicate the marked reduction of the 
functional RyR1 protein levels as an important common denominator in this group, with 
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impairment of calcium conductance rather than alterations of cytosolic or SR calcium levels as the 
most common downstream effect [19-21]. The precise function of selenoprotein N in muscle 
remains still uncertain but emerging evidence suggests a role in both antioxidant defense 
systems and (redox-regulated) calcium homeostasis: Selenoprotein N features a structural motif 
similar to those found in calcium-binding proteins [17] and, as demonstrated in normal zebrafish 
and the sepn1 -/- morphant, may be functionally and spatially associated with RyR1 [22, 23], 
providing a possible molecular basis for the many clinico-pathological similarities between 
RYR1- and SEPN1-related core myopathies.   
Because of the rapid recognition of RYR1 mutations as one of the most common 
causes of neuromuscular disorders in humans, therapy development for these conditions is a 
major goal within the congenital myopathy field. Possible therapeutic strategies currently 
considered or already tried include modification of abnormal RyR1 function, correction of 
associated oxidative abnormalities, use of pharmacological compounds enhancing muscle 
contractility and/or neuromuscular transmission, and correction of the specific genetic defect.  
Historically, the first pharmacological compound used to modify the abnormal Ca++ 
amount released during an MH crisis was dantrolene, an agent that was shown in early 
studies to reduce the maximal rate of SR Ca++ release [24] and inhibit caffeine induced ryanodine 
binding. In addition to its well-established role in MH management, dantrolene has also been used 
in the treatment of patients with RYR1-related  (exertional) rhabdomyolysis [25],  and anecdotal 
reports suggest that some patients with RYR1-related CCD may also benefit from dantrolene use 
[26, 27]. However, explorative use of dantrolene in RYR1-related myopathies ought probably to be 
limited to those carrying “leaky channel” mutations compared to those where calcium 
conductance is already reduced, considering that a RyR1 antagonist such as dantrolene  may 
potentially worsen the consequences of the molecular defect in the latter group.  
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RyR1 channels are situated within a highly complex macromolecular environment and 
undergo a number of dynamic modifications. One class of proteins involved in these complex 
interactions that have emerged as a possible pharmacological target for the treatment of RYR-
related cardiac and skeletal myopathies are the calstabins, including calstabin 1 (FK506 binding 
protein 12 or FKBP12) mainly expressed in skeletal muscle and calstabin 2 (FKBP12.6) mainly 
expressed in cardiac muscle (for review, [28, 29]). Calstabins act as RyR1 channel-stabilizing 
proteins that increase the channel probability of being closed at the resting state, but their 
dissociation from the RyR receptor under conditions of stress and with increased phosphorylation 
and nitrosylation results in “leaky” channels and, ultimately, in reduction of the available SR 
calcium stores. Two pharmacological compounds that have been demonstrated to reduce SR 
calcium leak by enhancing RyR1-calstabin interactions are the 1,4-benzothiazepine derivatives 
JTV519 and S107 (also known as Rycals), suggesting them as potential treatments also for 
RYR1-related myopathies associated with excessive calcium release such as MH or ERM, or 
with increased SR calcium leak such as subgroups of CCD [30]. Concerns remain regarding 
non-skeletal muscle effects of these compounds originally developed for the treatment of 
cardiac disease, and their effects in recessive RYR1-related myopathies where calcium 
conductance may already be impaired (and increasing RyR1 channel closed probability may 
potentially have a detrimental rather than a beneficial effect).      
Another compound that has been suggested to stabilize RyR1 function is 5-
aminoimidazole-4-carboximide ribonucleoside (or AICAR), an activator of the AMP-activated 
protein kinase (AMPK), a kinase and intracellular energy sensor upstream of the autophagy 
pathway. AICAR, a recognized enhancer of muscle performance [31], has recently been 
demonstrated to directly reduce RyR1 calcium leak and RNS and ROS production, an important 
aspect of the vicious cycle leading to fatal rhabdomyolysis in a mouse model of the human MH- 
and ERM- associated RYR1 mutation Y522S [32]. These findings suggest AICAR as a potential 
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treatment for RYR1-related myopathies associated with excessive calcium release or increased 
spontaneous calcium leak, but there are currently no data regarding its longterm use in human 
myopathies.                  
Another altogether different treatment approach is based on the observation of increased 
oxidative stress in patient cells and animal models. Recent studies have indicated that oxidative 
stress may be one of the causes underlying MH, and that oxidative stress is elevated in muscle of 
patients with MH and RYR1- and SEPN1-related myopathies [33-35]. A study on patient muscle 
cells and the zebrafish “relatively relaxed” mutant, a model of human recessive RYR1-related 
myopathies lacking the skeletal muscle ryr1b isoform, demonstrated elevation of oxidative stress 
markers and excessive production of reactive oxygen species of probable mitochondrial origin. 
Treatment with  200 µM N-acetylcysteine (NAC) reduced oxidative stress markers, decreased 
muscle damage and improved swimming abilities in the zebrafish mutant [35].  The use of 
antioxidants (and more specifically, NAC) is also supported by the fact that the RyR1 protein 
contains more than 100 cysteine residues, and that some of these (namely Cys residues at amino 
acid positions 1040, 1303, 2436, 2656, 2606, 2611 and 3635) are hyper-reactive and act as redox 
sensors which modulate the channel activity [36, 37]. Taken together, these observations have 
provided the rationale for the use of NAC as a potential treatment for RYR1- and SEPN1-related 
myopathies, and have prompted the first clinical trials in humans currently underway. However, 
there are presently no data regarding its longterm use in these conditions, and genetic determinants 
of altered oxidative stress susceptibility (such Glucose 6-phosphate dehydrogenase (G6PD) 
deficiency, one of the most common metabolic conditions worldwide) will have to be taken into 
account for the interpretation of clinical trials.  
Prompted by its previous use in other neuromuscular disorders, the β-agonist salbutamol 
has also been explored for the treatment of core myopathies with encouraging results in case 
reports and a small pilot study [26, 38, 39]. The precise mechanisms underlying the benefits of 
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salbutamol in core myopathies are uncertain, but may include an anabolic effect as seen in other 
β-mimetics, increases in relaxation speed and contractility as described in cardiac muscle [40], 
and/or enhancement of neuromuscular transmission.  
The feasibility of genetic strategies to treat RYR1-related myopathies has been 
demonstrated in one recessive case where exon skipping was successfully applied in vitro to 
remove an additional, paternally inherited exon associated with an unstable transcript and reduced 
RyR1 protein expression [41], resulting in increased expression of a functional RyR1 protein, and 
improved myotube morphology. Although these results are highly encouraging, a similar approach 
may only be applicable to the small number of pseudo-exon creating mutations in RYR1-related 
myopathies (estimated at 1-2%), as, in contrast to large structural proteins such as dystrophin, the 
RyR1 protein is unlikely to tolerate removal of whole exons through exon skipping considering its 
highly complex structure with probably little redundancy within functional domains. However, 
considering that even marked reduction of the functional RyR1 protein in carriers of recessive 
RYR1 mutations appears to be well tolerated [41, 42], targeted gene editing may become a feasible 
strategy to silence selected dominant RYR1 mutations associated with CCD in the future. A 
general caveat regarding the feasibility of gene therapy approaches to RYR1-related myopathies 
concerns the relative scarcity of recurrent RYR1 mutations, suggesting that many of these currently 
highly time consuming and costly targeted approaches may only benefit a small number of (or 
even isolated) families only.    
Potential for future therapy development in RYR1-related myopathies is suggested by 
the recent observation of altered expression levels of microRNAs (miRs) and histone deacetylyase 
(HDACs) in patients with recessive RYR1-related myopathies (for further details, see article by 
Treves et al in this issue) [43, 44]. MicroRNAs are endogenous small (around ~22 nucleotides), 
non-coding RNAs that control gene expression by repressing translation or enhancing RNA 
degradation and that have been implicated in several cardiac and skeletal muscle pathologies. 
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HDACs are involved in gene transcription and sequester the muscle specific transcription factor 
mef2 [45]. The overexpression of class II HDACs, in particular HDAC4 and 5, suggests those as 
potential pharmacological targets, however, the precise role of such overexpression has to be 
ascertained in the first instance before considering modulating them as a feasible therapeutic 
strategy.  
   
3. Myotubular/Centronuclear myopathy (MTM/CNM) 
 
Myotubular (or Centronuclear) Myopathies (MTM/CNM) are characterized by abundance 
of central nuclei on muscle biopsy (for review, [46]). CNM is due to X-linked recessive mutations 
in MTM1 encoding myotubularin [“X-linked myotubular myopathy (XLMTM)”] [47],  
autosomal-dominant mutations in DNM2 encoding dynamin2 [48] and the BIN1 gene encoding 
amphiphysin 2 [49], autosomal-recessive mutations in BIN1 [50], RYR1 [14], and TTN encoding 
titin [51], and rarer backgrounds [52-54]. Whilst mutations in MTM1 and BIN1 are typically 
associated with a “pure” CNM picture, histopathological appearance in particular in DNM2-, 
RYR1- and TTN-related forms is more variable and may also feature cores, CFTD and dystrophic 
features [14, 55, 56].  XLMTM due to X-linked recessive MTM1 mutations is one of the most 
devastating neuromuscular disorders in humans with profound weakness, marked respiratory 
impairment and substantial mortality in affected males, whereas mutations in DNM2, BIN1, TTN 
and RYR1 are associated with more variable but on the whole milder phenotypes (for review, 
[46]). Extraocular involvement is prominent in all forms except TTN-related CNM. Non-skeletal 
muscle involvement – for example hepatic peliosis in XLMTM [57], cataracts in DNM2-related 
CNM [58] and dilated cardiomyopathy in association with SPEG mutations [54] - has been 
reported with different genetic backgrounds.  
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A wide range of cellular and organismic models of the various genetic forms of CNM 
have been developed in recent years, as a basis for investigating underlying pathogenic 
mechanisms and as a prerequisite for therapy development (reviewed in [59]). The proteins 
initially implicated in CNM – myotubularin, dynamin 2 and amphiphysin 2 – are involved in 
intricately linked aspects of membrane trafficking and (re)modelling (reviewed in [60]). More 
specific pathogenic mechanisms (downstream of above “master mechanisms”) (reviewed in [59])  
include defects of triads and calcium handling,  autophagy , the neuromuscular junction, satellite 
cells, mitochondria, and the desmin cytoskeleton. RYR1-related CNM shares disturbed calcium 
homeostasis and excitation-contraction coupling as a common mechanism with other forms, but 
how mutations in TTN cause CNM is currently uncertain.    
Therapy development efforts in the CNMs have been mainly focussed on XLMTM, 
considering the profound severity of the disorder. The enzymatic functions of the myotubularin 
protein suggest enzyme replacement therapy as a therapeutic option, and the relatively small size 
of the MTM1 gene allows for therapies based on viral gene transfer-based gene therapy. Delivery 
of functional myotubularin applying an AAV8-based vector has now been demonstrated to 
improve the clinical and histopathological phenotype in Mtm1-deficient mice, and to increase 
muscle strength, reduce respiratory impairment and prolong survival in a canine model of 
XLMTM [61], the Labrador retriever [62].  Similar improvements of contractile function and 
histopathological features have been observed following short term myotubularin enzyme 
replacement in Mtm1d4 mice [63]. Results from these animal studies have been promising and 
have provided the basis for human enzyme replacement and gene therapy trials currently in 
preparation 
Another potentially promising avenue for future therapy development is prompted by 
recent experimental evidence indicating that dynamin 2 downregulation may rescue the XLMTM 
phenotype in mice [64], emphasizing the close interaction of several CNM proteins in the same 
Current therapeutic approaches to the congenital myopathies 12 
 
12 
 
pathway and suggesting dynamin 2 downregulation as a possible therapeutic strategy for 
XLMTM.    
As with for other conditions caused by heterozygous gain-of-function or dominant-
negative mutations, dominant forms of CNM due to DNM2 or BIN1 mutations may also be 
amenable to recently introduced gene editing strategies once those will approach the stage of 
clinical application [65].   
Another therapeutic approach is based on the observation of neuromuscular junction 
(NMJ) abnormalities in patients and animal models of CNM [66], and the clinical overlap between 
the CNMs and certain forms of congenital myasthenic syndromes (CMS), suggesting 
pharmacological compounds enhancing neuromuscular transmission as a potential treatment 
modality [67, 68]. One such compound, pyridostigmine, has already been demonstrated to be of 
benefit in patients with genetically confirmed and unresolved forms of CNM [67, 68]. Salbutamol 
is another drug that has been used effectively in certain subgroups of CMS and may also be of 
benefit in other congenital myopathies as outlined above [38]. However, those observations based 
on small pilot studies and no large placebo-controlled double-blind studies concerning these 
compounds have been performed yet.  
 
4. TTN-related myopathies 
 
Although recessive TTN mutations have been linked with CNM [51], there is considerable 
overlap with other congenital myopathies, in particular the core myopathies [8, 56], and TTN-
related myopathies are therefore covered here in a separate paragraph. The treatment approaches 
discussed below may also be potentially relevant to genes of similar size and mutation profiles 
such as NEB, and/or other proteins where abnormal aggregation may be an issue.    
Current therapeutic approaches to the congenital myopathies 13 
 
13 
 
Due to the large size of the TTN gene, its many exons, and a protein molecular weight of 
over 3 million Dalton, titin is highly susceptible to the stochastic impact of mutagenesis [69]. 
Premature stop-codons (caused by either mutations affecting correct splicing and leading to the 
inclusion of intronic sequences, or exonic nonsense mutations) as well as numerous missense 
variants abound in the TTN gene, with their functional impact and pathogenic relevance often 
difficult to ascertain. In CNM and other TTN-related Paediatric congenital myopathies reported to 
date, these variants are recessive [8, 51, 56, 70].  Although most TTN variants are private or very 
rare, some recessive missense variants have been linked to Autosomal-Recessive Multi-minicore 
Disease with Heart Disease (AR MmD-HD), with clear functional indication of structural 
disruption and complete loss of function of some key titin domains [8]. It appears that almost any 
combination of truncating and disruptive missense mutations in TTN can cause early-onset 
congenital myopathies with often vastly variable phenotypes, posing formidable challenges for 
accurate diagnostics but also for the development of therapeutic strategies that are realistically 
employable within the constraints of real clinical settings. Considering the main mutation 
mechanisms, several treatment strategies can be conceived and are pursued already in different 
contexts: 
(I) In the presence of nonsense mutations, restoring the mRNA reading frame (either by exon-
skipping or suppression of premature stop codons) could restore a functionally useful protein with 
largely intact mechanical and signalling functions and the potential to rescue or ameliorate the 
disease phenotype. This approach has been developed for the treatment of Duchenne muscular 
dystrophy (DMD), by exploiting initially the ability of certain aminoglycosides to enhance 
premature stop-codon read-through [71] and subsequent development of compounds with a 
similar mechanism of action but reduced toxicity such as PTC124 (Ataluren). Pharmacological 
suppression of premature stop codons is potentially applicable to a wide range of diseases, and 
pre-clinical and clinical studies are ongoing at various stages for DMD, cystic fibrosis, Werner 
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Syndrome and other conditions [72-75], and should clarify the long-term clinical outcomes in 
comparison to established therapies. This approach should also be applicable to TTN truncating 
nonsense mutations, informed by prior studies in cellular and/or animal titinopathy models as a 
screening platform for the feasibility of stop-codon read-through therapy. It is not yet clear if the 
efficacy of ataluren is high enough to restore functional levels of dystrophin or titin to regain 
significant structural integrity and function, which is clearly easier with enzymes or ion channels 
where (partial) functional rescue can be achieved with much lower stoichiometry. An interesting 
point is whether the simultaneous intervention in other loss-of-function loci will be beneficial. 
MacArthur et al (2014) estimated that the human genome contains around 100 loss-of-function 
variants, with about 20 genes completely inactivated [76]. The impact of these variants can be hard 
to predict, leading to loss of mRNA or protein by specific degradative pathways [77]. This might 
pose not only a diagnostic problem (which truncating gene variants are truly pathogenic?), but 
could also be a challenge for global pharmacological read-through therapy that would lead to the 
re-expression of such loss-of-function loci.  
(II) The use of protein-stabilising chaperone-like compounds (“chemical chaperones”) could be 
used to prevent the aggregation or degradation of misfolded titin domains carrying missense 
variants, or to promote their clearance by protein degradation pathways. This approach could 
alleviate the effects of proteotoxicity if a more normal function of the abnormal protein could be 
maintained.  The recent use of the chemical chaperone 4-phenylbutyrate (4-PBA) demonstrated 
that this simple compound is capable of ameliorating protein aggregate formation and restoring 
basic mechanical functions in cellular models of plectinopathy [78], although it remains to be seen 
if these promising results can be reproduced at the organismic level. The chemical nature of 4-
PBA leads to effects on multiple pathways, with a well-documented ability to inhibit histone 
deacetylases (HDAC) [79]. HDAC inhibition activates autophagy (for example, [80]), one of the 
two major ubiquitin-dependent protein degradation pathways, and it is possible that the stimulation 
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of autolysosomal degradation of protein aggregates and thus their reduced proteotoxicity, rather 
than primary prevention of misfolding, might be mechanistically important in skeletal muscle. 
Clearly, developing better and more specific small-molecule inhibitors of protein aggregation 
could therefore add significantly to the arsenal of hereditary myopathy therapy but might require 
tailored approaches for certain classes or types of mutations. [81] 
(III) In the case of haploinsufficiency, the absent protein would need to be restored if the above 
strategies are not effective. Current methods for gene delivery using chemical approaches or viral 
vectors are unsuited for gene or even protein delivery of a target with an mRNA of over 80 kb, 
making this last approach unlikely to be successful even in the medium future. 
(IV) Compounds that directly target the biological activity of the mutant protein to disrupt that 
pathomechanism at its causative root. Such drug discovery is in its infancy for hereditary 
myopathies, but recent advances for small molecules targeting mutant beta-myosin and alleviating 
heart disease progression in mouse models [82] suggest that such approaches might be feasible in 
some cases. However, better understanding of the underlying biology would be required to devise 
robust screening protocols.  
 
5. Nemaline Myopathy (NM) 
 
Nemaline myopathy (NM) is one of the more common congenital myopathies [2, 83, 84] 
characterized by numerous nemaline rods on muscle biopsy. To date, 10 genes have been linked to 
this disorder, including ACTA1, NEB, TPM3, TPM2, CFL2, TNNT1, LMOD3, KBTBD13, 
KLHL40, and KLHL41 [84-86] of which recessive mutations in NEB and (de novo) dominant 
mutations in ACTA1 are the most common. NM is associated with highly variable degrees of 
muscle weakness [2, 83, 84, 87] ranging from profoundly affected infants within the fetal akinesia 
spectrum to only mildly affected adult-onset cases. Bulbar and respiratory impairment are 
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common in many genetic forms but extraocular muscle involvement is not a typical feature, except 
in those due to mutations in the KLHL genes. 
Seven of the 10 genes implicated in NM - i.e., skeletal alpha-actin (ACTA1), nebulin 
(NEB), tropomyosin (TPM3 and TPM2), troponin T (TNNT1), cofilin (CFL2) and leiomodin-3 
(LMOD3) - encode proteins constituting the sarcomeric thin filament [88, 89]. The sarcomeric thin 
filament is an essential component of normal muscle function, through conformational changes 
allowing myosin head binding to actin monomers and, ultimately, force production, prompted by 
Ca2+ binding to one of its components, troponin C. To understand how NM-related mutations 
disrupt normal thin filament function, experimental studies have used muscle samples from NM 
patients or from mouse models reproducing the human condition [86, 90-96]. These studies have 
revealed that the absence of certain proteins (e.g. nebulin or skeletal alpha-actin), or the presence 
of mutated amino acids in skeletal alpha-actin and tropomyosin, alter Ca2+ binding, thin filament 
conformation and/or the interaction between myosin and actin molecules [86, 95, 97-108], 
resulting in reduced force generation at the sarcomere and, ultimately, skeletal muscle weakness.  
Despite improved understanding of the pathophysiological mechanisms underlying 
skeletal muscle weakness in NM, there is currently no cure and management is mainly 
symptomatic [109, 110], but a number of pharmacological compounds and supplements have 
been tested. Supported by preclinical data in a mouse model of ACTA1-related NM [90], a pilot 
study in 5 patients with NM suggested a beneficial effect of L-Tyrosine, with reduced fatigue and 
improvement of drooling [111]. A recent report of a single case with severe KLHL40-related NM 
suggested a sustained beneficial response to the acetylcholinesterase inhibitor pyridostigmine 
[112], indicating an associated neuromuscular transmission defect potentially amenable to 
treatment, corresponding to observations in other congenital myopathies, in particular the CNMs 
(see above).   
Considering the key role of thin filament dysfunction in NM, drugs targeting thin 
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filaments and their interactions directly have been recently developed [113, 114].  CK-2017357 
(Cytokinetics Inc.) binds to the Ca2+ sensor, troponin C, thereby facilitating force production by 
slowing the rate of Ca2+ release from troponin C and consequently favouring myosin activation 
and impairing the relaxation process [115]. However, a possible clinical benefit in NM is uncertain 
as CK-2017357 preferentially affects fast-twitch muscle fibres which are typically lacking in NM. 
Another compound, Omecamtiv Mecarbil (formerly termed CK-1827452) (Cytokinetics Inc.) 
attaches to myosin molecules and could be potentially advantageous for weak slow-twitch muscle 
fibres [116]. However, Omecamtiv Mecarbil also binds to cardiac myosin molecules, raising the 
possibility of cardiac complications if given to patients with NM.  
Considering the difficulties with directly targeting thin filament function, other therapeutic 
strategies are currently being developed. Muscle tissue from patients or animal models of NM 
contains a large number of atrophic fibres [2, 83, 84], suggesting increasing muscle fibre size and 
overall muscle mass by using myostatin inhibitors as a possible therapeutic strategy. Myostatin is a 
protein that is selectively expressed in skeletal muscle, cardiac muscle, and adipose tissue during 
late embryogenesis and adulthood and is an important negative regulator of muscle fibre size 
[117]. It binds to and signals through the activin type IIB receptor (ActRIIB) to down-regulate 
several key processes related to muscle fibre hypertrophy [117]. The potential for myostatin 
inhibition to promote muscle growth has led to development of a new class of myostatin and 
ActRIIB inhibitors as prospective therapeutic agents for myopathic, dystrophic and neurologic 
disorders [117], including NM but potentially also other congenital myopathies where fibre 
atrophy is a prominent feature such as XLMTM [118]. 
In the context of ACTA1-related NM, muscles from patients with rare null mutations partially 
compensate the absence of skeletal muscle α-actin by expressing the ACTC-associated protein, 
cardiac α-actin [119]. These findings have prompted investigation of cardiac α-actin upregulation 
as a possible therapeutic avenue in various mouse models of ACTA1-related NM. In one 
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transgenic line carrying the D286G mutation, muscle weakness and lethality were significantly 
reduced whilst in another model expressing H40Y, the up-regulation of ACTC did not have any 
noticeable positive or beneficial effect [120]. The mechanisms underlying such discrepancies 
remain to be determined. 
 
Congenital Fibre Type Disproportion 
 
Congenital fibre type disproportion (CFTD) is most commonly defined by type 1 fibers 
being at least 25% smaller than type 2 fibres in the absence of other pathological features on 
muscle biopsy (for review[121]). There is marked genetic and clinico-pathological overlap with 
other congenital myopathies, in particular NM and RYR1-related myopathies, and although in 
many patients the histopathological appearance of “pure” CFTD persists, in others additional 
histopathological features such as nemaline rods, central nuclei or cores may evolve over time [15, 
122-127]. CFTD is most commonly due to mutations in TPM3 and RYR1 and less frequently due 
to mutations in ACTA1 and SEPN1. Although there are currently no therapeutic approaches 
specifically aimed at CFTD, these disorders are likely to benefit from therapy developments in 
other closely related congenital myopathies.   
 
Conclusions and outlook 
 
Although there is currently no cure for any of the congenital myopathies, therapy 
development is rapidly progressing and informed by recent exponential advances concerning the 
genetic and molecular understanding of these conditions. Based on animal experimental evidence, 
gene therapy and enzyme replacement therapy trials are in preparation for X-linked myotubular 
myopathy (XLMTM), one of the most severe congenital myopathies. Clinical trials in humans 
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with acetylcysteine in humans with SEPN1- and RYR1-related myopathies are currently in 
progress, based on the observation of marked oxidative abnormalities as an important pathogenic 
mechanism in these conditions. Off-label use of drugs such as dantrolene, pyridostigmine and 
salbutamol appears to be of benefit in small open-label pilot studies, but those findings will have to 
be confirmed in larger double-blind, placebo-controlled clinical trials. Unravelling novel disease 
mechanisms may lead to the development of therapies potentially applicable to several genetically 
distinct subgroups in subgroups intricately linked in the same molecular pathways. Novel gene 
editing strategies may provide new therapeutic options in particular for dominantly inherited 
conditions in future but do raise significant ethical questions associated with direct manipulation of 
the human genome. 
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Figure and Table legends: 
 
Figure 1 
Schematic representation of pathogenic mechanisms implicated in the congenital 
myopathies (selection). A significant proportion of proteins involved in the congenital 
myopathies play a role in various aspects of Excitation-Contraction (EC) coupling, the process by 
which a neuronal impulse is translated into muscle contraction, mediated by calcium release from 
the sarcoplasmic reticulum (SR) into the cytosol and resulting in contractile thin/thick filament 
interactions.  Abnormalities of the triad, the ultrastructural correlate of the EC machinery, are also 
an important downstream effect of defective membrane formation and remodelling in various 
genetic forms of CNM due to mutations in MTM1, DNM2 and BIN1.  
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Table 1: Genetics of the major congenital myopathies. AD = autosomal dominant, AR = autosomal 
recessive,  XLR = X-linked recessive inheritance. The most common genetic backgrounds within each 
group are indicated in bold.  *typically combination of central nuclei and cores; **one isolated case 
with RYR1-related CNM and a de novo heterozygous missense mutations has also been reported.   
*** typically combination of (central) nuclei, (mini)cores and other myofibrillar abnormalities 
 GENE LOCUS INHERITANCE PROTEIN 
Nemaline myopathy     
 ACTA1   1q42 AD/AR skeletal α- actin 
 CFL2 14q12 AR Cofilin-2 
 KBTBD13 15q25 AD Kelch 13 
 KLHL40 3p21 AR Kelch-like 40 
 KLHL41 2q31 AR Kelch-like 41 
 NEB   2q.2  AR Nebulin 
 TPM2 9p13 AD/AR β-tropomyosin 
 TPM3 1q2 AD/AR α-tropomyosin 
 TNNT1 19q13 AR Troponin T 
Core myopathies     
Central Core Disease RYR1  19q13 AD/AR Ryanodine receptor 1 
Multiminicore Disease RYR1 19q13 AD/AR Ryanodine receptor 1 
 SEPN1 1p36 AR Selenoprotein N1 
+/- cardiomyopathy TTN 2q31 AR Titin 
 MYH7 14q11 AD slow myosin heavy 
chain 
Centronuclear myopathy     
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Myotubular myopathy MTM1  Xq28 XLR Myotubularin 
Centronuclear myopathy BIN1  2q14 AR Amphiphysin 
 CCDC78  16p13.3    AD*   coiled-coil domain- 
containing protein 78 
 DNM2 19p13 AD Dynamin-2 
 MYF6 12q21.31 AD Myogenic factor 6 
 RYR1 19q13 AR** Ryanodine receptor 1 
 SPEG 2q35 AR SPEG complex locus 
 TTN 2q31 AR*** Titin 
Congenital Fibre Type Disproportion 
 
    
 ACTA1 1q42 AD skeletal α-actin 
 HACD1 10p12 AR 3-hydroxyacyl-CoA 
dehydratase 1 
 MYH7 14q11 AD slow myosin heavy 
chain 
 RYR1 19q13 AR Ryanodine receptor 1 
 SEPN1 1p36 AR Selenoprotein N1 
 TPM2 9q13 AD β-tropomyosin 
 TPM3 1q2 AD α-tropomyosin 
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Table 2: Therapeutic approaches to the congenital myopathies.  * = first trials with N-
acetylcysteine currently in progress.  
Therapeutic approach CM Gene Type of study Reference 
     
Gene therapy     
Exon skipping CCD RYR1 Proof of Principle 41 
Gene transfer XLMTM MTM1 Proof of Principle 61 
     
Enzyme replacement     
Enzyme replacement therapy  XLMTM MTM1 Proof of Principle 63 
Modulation of SR calcium release     
Dantrolene MH, ERM RYR1 Case studies 26 
Dantrolene CCD RYR1 Case studies 27 
AICAR MH, ERM RYR1 Proof of Principle 32 
Rycals MH, CCD RYR1 Proof of Principle 29 
Modulation of neuromuscular 
transmission 
    
Pyridostigmine CNM MTM1 Open-label pilot 
study 
68 
Pyridostigmine NM KLHL40 Case study 112 
Salbutamol MmD, 
CCD 
RYR1 Open-label pilot 
study 
38 
Modulation of filament interaction     
CK-2017357 NM Various Proof of Principle 115 
CK-1827452 NM Various Proof of Principle 116 
Other approaches     
     
Myostatin inhibition CNM MTM1 Proof of Principle 118 
N-acetylcysteine CCD RYR1 Proof of 
Principle* 
35 
N-acetylcysteine MmD SEPN1 Proof of 
Principle* 
35 
 
